ArticleThe journal of allergy and clinical immunology. In practice2020
Exacerbation-Prone Asthma.
Article in The journal of allergy and clinical immunology. In practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 65 citations in OpenAlex.
- Cathepsin C orchestrates RSV-induced asthma exacerbation through the dual effect of monocyte-derived macrophages.Cellular & molecular immunology · 2026Article
- Severe Asthma Exacerbations: From Risk Factors to Precision Management Strategies.Journal of clinical medicine · 2026Review
- Inhalant Allergen Sensitization: Prevalence, Risk Factors, and Geographic Variation in the USA.International archives of allergy and immunology · 2026Article
- The Interlinkages Between Ambient Temperature and Air Pollution in Exacerbating Childhood Asthma: A Time Series Study in Cape Town, South Africa.Children (Basel, Switzerland) · 2025Article
- Determinants of airway morphology in asthma: Inflammatory and noninflammatory factors.The journal of allergy and clinical immunology. Global · 2025Article
- Child Opportunity Index at birth and asthma with recurrent exacerbations in the US ECHO program.The Journal of allergy and clinical immunology · 2025Article
- Exploring the perception and needs of pharmaceutical care among family caregivers of pediatric asthma patients in Guangdong Province, China: a cross-sectional survey study.BMC primary care · 2025Article
- Risk factors for asthma exacerbations.The journal of allergy and clinical immunology. Global · 2025Article
- Frequent exacerbator-a novel endotype of pediatric asthma.The Journal of allergy and clinical immunology · 2025Review
- Impact of the COVID-19 Pandemic on Lung Function and Treatment Decisions in Children with Asthma: A Retrospective Study.Journal of clinical medicine · 2025Article
- Short-term exposure to fine particulate matter and asthma exacerbation: a large population-based case-crossover study in Southern Thailand.Environmental health : a global access science source · 2025Article
- A Retrospective Study Evaluating Asthma Control in Patients on Fluticasone Propionate/Salmeterol Proactive Regular Dosing with a History of Uncontrolled Asthma.Pulmonary therapy · 2025Article
- Possible Involvement of Lysophospholipids in Severe Asthma as Novel Lipid Mediators.Biomolecules · 2025Review
- Non-Pharmaceutical Interventions May Attenuate Acute Exacerbations of Asthma: Experience During the COVID-19 Pandemic in Taiwan.Journal of asthma and allergy · 2025Article
- Effects ofFrontiers in allergy · 2025Article
- Characteristics of children with severe preschool asthma prior to starting the TIPP study.Frontiers in pediatrics · 2025Article
- Environmental pollutant 3-methyl-4-nitrophenol promotes the expression of oncostatin M to exacerbate airway allergic inflammation.Clinical and experimental immunology · 2024Article
- Exacerbations of bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Socioeconomic status, diet, and recurrent severe asthma exacerbations in Puerto Rican youth.The journal of allergy and clinical immunology. Global · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Patients who are prone to exacerbations of asthma experience significant costs in terms of missed work and school, acute care visits, and hospitalizations. Exacerbations are largely driven by environmental exposures including pollutants, stress, and viral and bacterial pathogens. These exposures are most likely to induce acute severe "asthma attacks" in high-risk patients. These personal risk factors for exacerbations can vary with the phenotype of asthma and age of the patient. In children, allergic sensitization is a strong risk factor, especially for those children who develop sensitization early in life. Airway inflammation is an important risk factor, and biomarkers are under evaluation for utility in detecting eosinophilic and type 2 inflammation and neutrophilic inflammation as indicators of risk for recurrent exacerbations. Insights into inflammatory mechanisms have led to new approaches to prevent exacerbations using mAb-based biologics that target specific type 2 pathways. Challenges remain in developing an evidence base to support precision interventions with these effective yet expensive therapies, and in determining whether these treatments will be safe and effective in young children. Unfortunately, there has been less progress in developing treatments for acute exacerbations. Hopefully, greater understanding of mechanisms relating airway viruses, bacteria, mucin production, and neutrophilic inflammatory responses will lead to additional treatment options for patients experiencing acute exacerbations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.